MedTrace Logo

The STOP-HPV Scale Up Study

NCT06831383 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100000

Last updated 2026-05-19

No results posted yet for this study

Summary

Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only ("STOP-HPV-Online" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads ("STOP-HPV-LC).

cer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation/completion rates in the U.S. were only at 76.8%/61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.

Conditions

  • Human Papilloma Virus Vaccine

Interventions

BEHAVIORAL

STOP-HPV-Online

Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-Online intervention.

BEHAVIORAL

STOP-HPV-LC

Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-LC intervention.

Sponsors & Collaborators

Principal Investigators

  • Peter Szilagyi, MD, MPH · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2027-04-19
Completion
2027-04-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06831383 on ClinicalTrials.gov